文献速递心力衰竭与心肌病心律失常瓣膜病与结构性心脏病

活检证实与临床诊断心脏结节病的比较

Comparisons between biopsy-proven versus clinically diagnosed cardiac sarcoidosis.
PubMed 文献 · Heart · 2022-11-10

研究纳入512例心脏结节病患者,其中活检证实314例(61.3%),临床诊断198例(38.7%)。中位随访43.7个月,两组主要复合终点风险无显著差异(调整HR:1.24,95%CI:0.88至1.75,p=0.22)。临床诊断的心脏结节病在影像学提示下是可接受的。

要点

  • 临床诊断心脏结节病占38.7%,与活检证实者预后相当。
  • 临床诊断组更常见左室功能不全、室间隔变薄及PET/镓显像阳性。
  • 无组织学证据时,依据典型影像学表现诊断心脏结节病是合理的。

核心结论

  • 临床诊断心脏结节病与活检证实者主要复合终点风险相当(调整HR:1.24,95%CI:0.88至1.75,p=0.22)。
  • 临床孤立性心脏结节病与活检证实的孤立性心脏结节病风险亦相当(调整HR:1.23,95%CI:0.56至2.70,p=0.61)。

研究设计与样本

  • 多中心注册研究,纳入512例心脏结节病患者(年龄62±11岁,女性64.3%)。
  • 按组织学证据分为活检证实组(314例,61.3%)和临床诊断组(198例,38.7%)。
  • 主要终点为全因死亡、心力衰竭住院和室性心律失常事件的复合终点。

主要发现

  • 临床诊断组左室功能不全、室间隔变薄及FDG-PET或镓显像阳性的患病率高于活检证实组。
  • 中位随访43.7(23.3-77.3)个月,两组主要终点风险无显著差异。
  • 临床孤立性心脏结节病与活检证实的孤立性心脏结节病主要终点风险无显著差异。

关键数值与推荐

  • 临床诊断依据Heart Rhythm Society或日本循环学会标准判定。
  • 活检证实组为组织学确诊;临床诊断组为无组织学证据但临床高度提示。

临床怎么用

  • 对于影像学高度提示心脏结节病但无组织学证据的患者,可考虑临床诊断并启动管理。
  • 临床诊断的心脏结节病与活检证实者预后相似,不应因缺乏活检而延迟诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Diagnosis of cardiac sarcoidosis (CS) without histological evidence remains controversial. This study aimed to compare characteristics and outcomes of histologically proven versus clinically diagnosed cases of CS, which were adjudicated using Heart Rhythm Society or Japanese Circulation Society criteria. METHODS: A total of 512 patients with CS (age: 62±11 years, female: 64.3%) enrolled in the multicentre registry were studied. Histologically confirmed patients were classified as 'biopsy-proven CS', while those with the presence of strongly suggestive clinical findings of CS without histological evidence were classified as 'clinical CS'. Primary outcome was a composite of all-cause death, heart failure hospitalisation and ventricular arrhythmia event. RESULTS: In total, 314 patients (61.3%) were classified as biopsy-proven CS, while 198 (38.7%) were classified as clinical CS. Patients classified under clinical CS were associated with higher prevalence of left ventricular dysfunction, septal thinning, and positive findings in fluorodeoxyglucose-positron emission tomography or Gallium scintigraphy than those under biopsy-proven CS. During median follow-up of 43.7 (23.3-77.3) months, risk of primary outcome was comparable between the groups (adjusted HR: 1.24, 95% CI: 0.88 to 1.75, p=0.22). Similarly, the risks of primary outcome were comparable between patients with clinical isolated CS who did not have other organ/tissue involvement, and biopsy-proven isolated CS (adjusted HR: 1.23, 95% CI: 0.56 to 2.70, p=0.61). CONCLUSIONS: A substantial number of patients were diagnosed with clinical CS without confirmatory biopsy. Considering the worse clinical outcomes irrespective of the histological evidence, the diagnosis of clinical CS is justifiable if imaging findings suggestive of CS are observed.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Kitai T, Nabeta T, Naruse Y, et al. Comparisons between biopsy-proven versus clinically diagnosed cardiac sarcoidosis. Heart. 2022. PMID: 35790370. doi:10.1136/heartjnl-2022-320932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。